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OBJECTIVES We hypothesized that angiotensin II type-1 (AT1) receptor blocker (AT1RB) would prevent
adverse left ventricular (LV) remodeling and LV dysfunction when started at the outset of
mitral regurgitation (MR).
BACKGROUND Little is known regarding the efficacy of AT1RB treatment of MR.
METHODS Mitral regurgitation was induced by chordal disruption in adult mongrel dogs. Six normal
dogs (NLs) were compared to six untreated MR dogs (MR) and seven dogs treated with the
receptor blocker irbesartan (MRAT1RB) started 24 h after induction of MR (60 mg/kg p.o.
b.i.d.) and continued for three months.
RESULTS Treatment with AT1RB decreased systemic vascular resistance but did not significantly
improve cardiac output, LV end-diastolic dimension (LVEDD) or LVEDD/wall thickness
compared to untreated MR dogs. Resting isolated cardiomyocyte length increased in MR
versus NLs and was further increased in AT1RB dogs. Left ventricular end-systolic
dimension increased to a greater extent from baseline in AT1RB dogs versus untreated MR
dogs (29  9% vs. 12  6%, p  0.05), despite a significantly lower LV peak systolic pressure
in AT1RB dogs. Plasma-angiotensin (ANG) II was elevated greater than threefold in both
MR and MRAT1RB versus NLs. In contrast, intracardiac ANG II was increased greater
than twofold in MR dogs versus NLs, but was normalized by AT1RB.
CONCLUSIONS The use of AT1RB decreased systemic vascular resistance and attenuated local expression of
the renin-angiotensin system but did not prevent adverse LV chamber and cardiomyocyte
remodeling. These results suggest that blockade of the AT1 receptor does not improve LV
remodeling and function in the early myocardial adaptive phase of MR. (J Am Coll Cardiol
2002;39:1374–9) © 2002 by the American College of Cardiology Foundation
Chronic hemodynamic stress results in neurohormonal
activation that can lead to adverse cardiac remodeling and
congestive heart failure (CHF), both by an adverse effect of
systemic hemodynamics, and by a direct effect on the
myocardium. Blockade of the renin-angiotensin system
(RAS) with angiotensin-converting enzyme (ACE) inhibi-
tors has been demonstrated to modulate adverse left ven-
tricular (LV) remodeling and beneficially alter the natural
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history in experimental animal models as well as in clinical
trials of CHF. The underlying etiology of heart failure
cardiomyopathy in the major ACE inhibitor clinical trials
has predominantly been coronary disease, hypertension or
idiopathic. There is surprisingly little information regarding
the long-term efficacy of RAS inhibition in CHF due to
pure valvular incompetence, as patients with primary valvu-
lar incompetence have been consistently excluded from the
large randomized ACE inhibitor and angiotensin II type-1
receptor blocker (AT1RB) trials of heart failure (1–6).
We have recently reported that chronic treatment with
the ACE inhibitor ramipril 10 mg b.i.d. failed to attenuate
adverse LV remodeling or the increase in cardiomyocyte
length in dogs with chronic mitral regurgitation (MR) (7),
despite a decrease in pulmonary capillary wedge pressure
and reduction of LV angiotensin (ANG) II levels to normal.
The reason for the failure of ACE inhibitors to prevent
adverse remodeling in chronic MR, despite normalization of
tissue ANG II and in contrast to the beneficial effects of
these agents in multiple other etiologies of CHF, is uncer-
tain. The LV ANG II levels were decreased, but not below
normal levels in the MR dogs, possibly owing to the presence
of chymase in the dog heart. Furthermore, angiotensin II
type-1 (AT1) receptor expression increased significantly with
chronic ACE inhibitor treatment (7), raising the possibility of
an enhanced action of ANG II in the presence of normal tissue
stores. In the current study, we test the hypothesis that AT1
receptor blockade favorably influences LV chamber and cardi-
omyocyte function and remodeling in dogs with chronic MR
induced by chordal disruption.
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METHODS
Experimental preparation. Mitral regurgitation was in-
duced at Auburn University College of Veterinary Medicine
(Auburn, Alabama) in conditioned mongrel dogs of either
gender (19 to 26 kg) by chordal rupture using a fluoroscopic
guided catheterization method previously described in our
laboratory (7,8). Dogs were randomly assigned to one of
three groups: 1) three months of chronic MR (n  6); 2)
three months of chronic MR and treatment with the AT1
receptor antagonist (irbesartan, 60 mg/kg p.o., twice daily;
n  7) starting 24 h after MR induction; and 3) unoperated
controls (n  6). We have previously demonstrated that
irbesartan given 30 mg/kg p.o. b.i.d. for three days produced
a 70% inhibition of ANG II pressor response 6 h after the
last dose. A dose of 60 mg/kg p.o. b.i.d. achieved a 70%
depression of ANG II pressor response at 12 h after the last
dose (9). In the current proposal, doses were titrated up to
60 mg/kg p.o. b.i.d. as systemic blood pressure permitted.
At the conclusion of the study period, the dogs were
transferred to the Medical University of South Carolina at
Charleston where echocardiography and catheterization
were performed prior to sacrifice. This study was approved
by the Animal Services Committees at the University of
Alabama at Birmingham, Auburn University College of
Veterinary Medicine and the Medical University of South
Carolina at Charleston.
Terminal catheterization study. Two-dimensional and
M-mode echocardiography (ATL Ultramark VI, 2.25 MHz
transducer, Bothell, Washington) were used to image the
LV from a right parasternal approach (10). Electrocardio-
graphic monitoring was established and the dogs anesthe-
tized as previously described (7,8). A multilumen thermodi-
lution catheter (7.5F, Baxter Healthcare, Irvine, California)
was inserted into the left jugular vein and positioned in the
pulmonary artery for measurement of thermodilution car-
diac output and for pulmonary artery and pulmonary cap-
illary wedge pressures. A precalibrated 7F micromanometer
catheter (PPG Biomedical Systems, Pleasantville, New
York) was advanced through the left carotid artery into the
LV. A fluid-filled 7F catheter was advanced into the
abdominal aorta from the right femoral artery for aortic
pressure measurements.
The LV fractional shortening was calculated from the
echocardiographic measurements as: (end-diastolic dimen-
sion  end-systolic dimension)/end diastolic dimension
(%). The LV peak and end-systolic (defined at peak 
dP/dt) circumferential wall stress was computed using a
spherical model:
g/cm2  PD/4 h 1  h/D	  1.36
where P  systolic blood pressure, D  minor axis
dimension and h  wall thickness (10). The LV forward
stroke volume was computed as the thermodilution cardiac
output/heart rate. The LV regurgitant fraction (%) was
computed as: (echocardiographic-determined stroke volume
 thermodilution stroke volume)/echocardiographic stroke
volume. Echocardiographic volumes were computed based
upon previously validated formulae for dogs in both the
normal and MR state (10).
Following the catheterization measurements, a sternot-
omy was performed, and the heart quickly extirpated, placed
in a phosphate-buffered ice slush and the coronaries flushed
with oxygenated Krebs solution. The great vessels were
removed at the aortic and pulmonary valves and the right
ventricle and LV quickly weighed. The LV was cut into 1 

1 
 1-cm cubes and snap-frozen in liquid nitrogen for
subsequent biochemical studies. The region of the LV free
wall incorporating the circumflex artery (5 
 5 cm) was
excised and prepared for myocyte isolation. Left ventricular
myocytes were harvested using techniques described previ-
ously (9).
CARDIAC ANG II CONCENTRATIONS. Plasma and cardiac
ANG II concentrations were determined as previously
described from our laboratory by a method that combines
solid-phase extraction, high-performance liquid chromatog-
raphy and radioimmunoassay (7,8).
CARDIAC ACE AND CHYMASE ACTIVITIES. Cardiac ACE
activity was measured with an assay developed in our
laboratory, which uses the ACE-specific artificial substrate
hippuryl histidyl leucine and quantifies the product hippuric
acid by ultraviolet detection at 228 nm (7,8,11). The ACE
is extracted from homogenized cardiac tissue with deter-
gent, and the reaction product hippuric acid is isolated from
the reaction mixture by reverse-phase HPLC, thus elimi-
nating interference from the detergent, the ACE-specific
substrate hippuryl histidyl leucine, and unreacted reaction
by-products.
Chymase activity was assayed as previously reported by
our laboratory (7,8). Generated ANG II was quantitated
using a Reversed-Phase Alltima 5-m phenyl-HPLC col-
umn (Alltech, Deerfield, Illinois). The peak area corre-
sponding to a synthetic ANG II standard was integrated to
calculate ANG II formation. Chymostatin-inhibitable
ANG II formation was considered to represent the
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANG  angiotensin
ANOVA  analysis of variance
AT1  angiotensin II type-1 receptor
AT2  angiotensin II type-2 receptor
AT1RB  angiotensin II type-1 receptor blocker
CHF  congestive heart failure
LV  left ventricle/ventricular
LVEDD  left ventricular end-diastolic dimension
LVESD  left ventricular end-systolic dimension
LVESS  left ventricular end systolic stress
LVESV  left ventricular end systolic volume
MR  mitral regurgitation
NL  normal dogs
RAS  renin-angiotensin system
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chymase-like activity, expressed as nanomoles of ANG II
formed per minute per gram of tissue (wet wt).
Data analysis. Indices of LV function, systemic hemody-
namics and biochemistry were compared among the treat-
ment groups using analysis of variance (ANOVA). If the
ANOVA revealed significant differences, pairwise tests of
individual group means were compared using Bonferroni
probabilities. For comparisons of neurohormonal profiles,
the Student-Newman-Keuls test was employed. The treat-
ment effects were MR and drug therapy. Each dog was
considered a complete block. All statistical procedures were
performed using the BMDP statistical software package
(BMDP Statistical Software, Los Angeles, California).
Results are presented as mean  SEM. Values of p  0.05
were considered to be statistically significant.
RESULTS
Hemodynamics. Systemic vascular resistance was in-
creased twofold in untreated MR dogs. The AT1RB de-
creased systemic vascular resistance to normal levels (p 
0.05, MR vs. MRAT1RB). Cardiac output was signifi-
cantly decreased in untreated MR dogs versus normal dogs
(NLs) (p  0.05) but did not differ in MRAT1RB versus
NLs. Mean pulmonary artery pressure and pulmonary
capillary wedge pressure were likewise significantly elevated
in MR dogs compared to NLs and intermediate in
MRAT1RB dogs.
Left ventricular mass/body weight was increased in both
MR and MRAT1RB compared to NLs. The LV mass/
body weight was less in the MRAT1RB versus MR dogs,
but this did not achieve statistical significance. The LV
end-diastolic dimension (LVEDD), LV end-diastolic vol-
ume, LVEDD/wall thickness ratio and LV end-diastolic
wall stress increased to a similar extent in the untreated MR
and MRAT1RB dogs compared to NLs. In parallel with
the eccentric LV chamber remodeling, resting cardiomyo-
cyte length was increased in both MR and MRAT1RB
dogs compared to NLs (164.9  0.8 m and 173.7 
0.8 m versus 144.5  0.7 m, respectively, p  0.05,
Table 1). However, cardiomyocyte length was greater in the
MRAT1RB compared to MR dogs (p  0.05).
Left ventricular peak positive dP/dt was significantly
depressed in both MR and MRAT1RB dogs compared to
NLs. Both LV end-systolic dimension (LVESD) and LV
end-systolic volume (LVESV) increased significantly with
MR in both groups; however, there was a trend toward a
greater increase in LVESV in MRAT1RB versus MR
dogs (p  0.05). This trend, coupled with a LV peak
systolic pressure that was significantly lower in
MRAT1RB dogs, suggested greater contractile depression
in MRAT1RB dogs. Similarly, the LV end-systolic stress
(LVESS)/LVESV ratio was significantly depressed in the
MRAT1RB versus NLs (p  0.05). The LVESS/LVESV
depression was intermediate in untreated MR dogs, com-
Table 1. Left Ventricular Function and Hemodynamics in MR: Effect of AT1RB
NL MR MR AT1RB
Heart rate (beats/min) 111  9 105  6 108  7
Mean arterial pressure (mm Hg) 96  5 92  7 77  3*†
Mean pulmonary artery pressure (mm Hg) 7.3  0.9 14.1  3.0* 12.0  1.6
Pulmonary capillary wedge pressure (mm Hg) 4.8  0.6 11.7  2.2* 8.7  1.6
Total systemic resistance (dynescm5) 2673  651 4675  707* 2728  326†
Cardiac output (l/min) 3.9  1.0 1.8  0.4* 2.5  0.3
LV forward stroke volume (ml) 33.9  6.2 16.9  2.5* 23.0  2.4*
Regurgitant stroke volume (ml) — 54  8 59  13
LV mass to body weight ratio (g/kg) 4.1  0.5 6.7  0.4* 5.9  0.5*
Cardiomyocyte length (m) 144.5  0.7 164.9  0.8* 173.7  0.8*†
LV fractional shortening (%) 43  3 45  2 42  4
LVEDD (cm) 3.7  0.1 5.1  0.1* 5.3  0.3*
LVESD (cm) 2.1  0.1 2.8  0.1* 3.1  0.3*
LV end-diastolic volume (ml) 44  4 99  7* 116  17*
LVESV (ml) 12  1 25  3* 35  6*
LV ejection fraction (%) 72  3 75  2.1 71  4
LV end-diastolic wall thickness (cm) 1.02  0.03 0.71  0.02* 0.75  0.02*
LVEDD/LV wall thickness ratio 3.6  0.1 7.3  0.3* 7.1  0.3*
LV peak systolic pressure (mm Hg) 123  3 116  8 101  4*†
LV end-diastolic pressure (mm Hg) 4.8  0.8 9.9  1.3* 8.0  1.4*
Maximum  LV dP/dt (mm Hg/s) 2,309  227 1,717  193* 1,688  68*
LV peak systolic wall stress (g/cm2) 121  4 253  24* 217  17*
LV end systolic wall stress (g/cm2) 26.1  4.9 39.3  5.2 39.0  7.1
LVESS/LVESV ratio (g/cm2/cc) 2.4  0.4 1.7  0.1 1.3  0.2*
LV end-diastolic wall stress (g/cm2) 5  1 21  3* 18  3*
Sample size (n) 6 6 7
*p  0.05 vs. Control. †p  0.05 vs. MR. Values presented as mean  SEM.
AT1RB  angiotensin type-1 receptor blocker; LV  left ventricle/ventricular; LVEDD  left ventricular end-diastolic
dimension; LVESD  left ventricular end-systolic dimension; LVESS  left ventricular end-systolic stress; LVESV  left
ventricular end-systolic volume; MR  mitral regurgitation; NL  normal dogs.
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pared to NLs and MRAT1RB (p  0.10 for MR vs. NLs,
and MR vs. MRAT1RB).
To correct for potential baseline differences in LV cham-
ber size between groups, the percent change in LV chamber
dimensions from baseline to three months was calculated for
MR and MRAT1RB dogs (Table 2). Baseline LVEDD,
LVESD and fractional shortening did not differ signifi-
cantly between MR and MRAT1RB dogs. Percent
changes in LVEDD (33  5 vs. 40  9% increase) and in
fractional shortening (40  14 vs. 27  7% increase) did not
differ in MR versus MRAT1RB dogs. However, LVESD
increased to a greater extent from baseline in MRAT1RB
versus MR dogs (29  9 vs. 12  6%, p  0.05). Taken
together, AT1RB did not improve function or remodeling
despite reductions in blood pressure and systemic vascular
resistance.
LV ACE and chymase activity, ANG peptide levels and
plasma renin activity. Plasma renin activity and plasma
ANG I and ANG II increased threefold in MR and fivefold
in MRAT1RB dogs (Fig. 1). The LV ANG II levels were
increased twofold in MR compared to NLs (p  0.05) but
decreased significantly in MRAT1RB dogs to levels not
significantly different from NLs (Fig. 2). Left ventricular
midwall ACE activity increased more than twofold in MR
versus NLs (p  0.05) and decreased in MRAT1RB to
levels not significantly different from NLs (Fig. 2). Chymase
activity did not differ among groups.
DISCUSSION
The unique findings of this study were that AT1RB, which
was initiated immediately after induction of MR and
continued throughout the ensuing three months, failed to
prevent LV hypertrophy, eccentric LV remodeling and
elongation of cardiomyocytes. Further, there was evidence
of a greater percent increase in LVESD and greater elon-
gation of cardiomyocytes in the dogs treated with AT1RB
compared with untreated MR dogs. Thus, AT1RB de-
creased systemic vascular resistance and reduced local ex-
pression of the RAS but did not result in an improvement
in LV function or remodeling.
Cardiac RAS in MR. There was evidence of effective AT1
receptor blockade both at the plasma and tissue levels.
Plasma renin activity and plasma ANG II were elevated in
MR dogs and increased further in the AT1RB dogs,
reflecting disinhibition of renin release by AT1RB. In tissue,
LV ACE activity and ANG II concentrations, both of
which were elevated in MR dogs, were normalized by
AT1RB. Hemodynamic changes most likely do not account
for the normalization of LV ACE, as the latter correlates
most closely with diastolic wall stress (7), which did not
differ significantly between MR and AT1RB dogs. The
angiotensin type-2 (AT2) receptor knockout mice have
increased tissue ACE activity (12), suggesting that stimu-
lation of the AT2 receptor inhibits tissue ACE formation.
Thus, unopposed AT2 receptor stimulation due to AT1RB
may account for the decrease in LV ACE in AT1RB dogs.
Table 2. Change From Baseline in Echocardiograph-
Derived Parameters
Baseline 3 Months % Change
LVEDD (cm)
MR 3.8  0.1 5.1  0.1† 32.9  4.9†
MRAT1RB 3.8  0.2 5.3  0.3† 40.2  8.9†
LVESD (cm)
MR 2.6  0.1 2.8  0.1 12.2  5.9*†
MRAT1RB 2.6  0.2 3.1  0.3† 28.9  8.8*†
Fractional shortening (%)
MR 33.5  2.7 45.4  1.9† 40.2  13.6†
MRAT1RB 32.8  2.1 41.8  3.8† 27.2  7.0†
*p  0.05 vs. MR. †p  0.05 vs. baseline. Values presented as mean  SEM.
AT1RB  angiotensin II type-1 receptor blocker; LVEDD  left ventricular
end-diastolic dimension; LVESD  left ventricular end-systolic dimension; MR 
mitral regurgitation.
Figure 1. Plasma renin activity: angiotensin (ANG) I and ANG II levels
are increased in mitral regurgitation (MR) and MRAT1RB compared to
normal (NL) dogs. *p  0.01 MRAT1RB and MR vs. normal dogs.
AT1RB  angiotensin II type-1 receptor blocker.
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Decreased LV ACE activity may account in part for the
decrease in LV ANG II.
In addition, recent studies have demonstrated that co-
infusion of exogenous ANG II and AT1RB in the normal
intact pig (13) and in the isolated rat heart (14) results in
lower tissue and interstitial fluid ANG II levels compared to
infusion of ANG II alone. These findings are thought to be
due to decreased cellular internalization of ANG II as a
result of blockade of the AT1 receptor, resulting in increased
degradation of ANG II by extracellular peptidases. Thus,
this mechanism may, in part, explain the normalized LV
ANG II levels in MRAT1RB dogs.
Effect of RAS blockade in MR in humans. The failure to
improve eccentric LV remodeling or LV function in
AT1RB dogs is certainly counterintuitive in the face of
significant decreases in systemic vascular resistance and LV
peak systolic pressure. However, clinical studies of chronic
ACE inhibitor therapy in MR have also reported conflicting
results. In a comprehensive review of these studies, Levine
and Gaasch (15) concluded that the efficacy of ACE
inhibitors in MR depended on their effect on regurgitant
orifice area, which in turn depended on the underlying
etiology of MR. They postulated that the observed efficacy
of ACE inhibitor in papillary muscle dysfunction or dilated
cardiomyopathy was due to a decrease in LV size and
thereby in regurgitant orifice area as a result of afterload
reduction. In contrast, ACE inhibitors were ineffective in
rheumatic MR, which tends to have a fixed orifice area, and
in mitral valve prolapse, a condition in which preload or
afterload reduction may actually increase the prolapse and
severity of MR (15). This could in part explain the failure of
AT1RB to reduce regurgitant volume and LV remodeling in
our dogs with chordal rupture.
Effect of RAS blockade in dog model of MR. The
LVESD increased to a greater extent from baseline in
AT1RB dogs versus untreated MR dogs, despite a signifi-
cant reduction in systemic vascular resistance and LV peak
systolic pressure. A previous study demonstrated that acute
beta-blockade unmasked significant innate LV contractile
depression after three months of MR in the dog (16). Thus,
the adrenergic nervous system is extremely important in
maintaining contractile function in the subacute phase of
this canine model of MR. In the current investigation,
AT1RB was initiated within 24 h, most likely before
steady-state myocardial compensation. In addition to its
trophic effects on cardiomyocytes, ANG II has also been
shown to have a positive myocardial inotropic effect either
directly or indirectly via activation of AT1 receptors on
nerve terminals in the heart with subsequent release of
norepinephrine (17). Indeed, we have recently shown that
exogenous infusion of ANG II into the heart causes release
of cardiac norepinephrine and epinephrine into the inter-
stitial fluid space of the hearts of dogs in vivo, even in the
absence of adrenal input (18). Thus, blockade of the AT1
receptor may have prevented important inotropic support of
the heart in the early adaptive phase of MR, thereby
resulting in the discordance between the drug-mediated
vasodilation and LV shortening.
In addition to the hemodynamic considerations noted in
the preceding text, there are important morphometric fea-
tures of MR that may account for the failure of ACE
inhibitor and AT1RB to prevent LV remodeling. The
efficacy of the RAS blockade has been documented largely
in clinical trials and in experimental animal models in the
setting of postmyocardial infarction, hypertension or idio-
pathic dilated cardiomyopathy. In general, these conditions
are characterized by increased collagen deposition in the
extracellular matrix of the myocardium. The beneficial
effects of RAS inhibition are mediated in part by suppres-
sion or reversal of this fibrosis (19). The canine model of
MR, however, is characterized by an absence of fibrosis and
by dissolution of the fine collagen weave (7). In fact, we
found a tendency toward increased dissolution of collagen
weave and increased cardiomyocyte length in the ACE-
inhibitor-treated MR dogs, compared to untreated MR
dogs (7). Loss of the fine collagen weave destroys the
structural support of the extracellular matrix that is neces-
sary for maintenance of normal LV chamber geometry and
for the translation of forces from individual cardiomyocytes
to the LV chamber (20). Thus, our failure to see a favorable
effect of either AT1RB or ACE inhibitor on LV remodel-
Figure 2. Left ventricular (LV) angiotensin (ANG) II concentrations and
LV angiotensin-converting enzyme (ACE) activity levels in normal, mitral
regurgitation (MR) and MRAT1RB dogs demonstrating that ANG II
and ACE were increased greater than twofold in MR dogs vs. normals, but
were normalized by AT1RB. *p  0.05 MR vs. normal dogs. AT1RB 
angiotensin II type-1 receptor blocker.
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ing, myocyte lengthening or LV function following three
months of MR may reflect an absence of fibrosis and
pre-existing matrix degradation, in which RAS blockade
may have a neutral or even deleterious effect.
Conclusions. Angiotensin II type-1 receptor blockade,
which was begun shortly after the induction of MR, lowered
systemic vascular resistance and decreased LV ANG II
levels but did not improve LV remodeling or function in
dogs in the early myocardial adaptive phase of MR. These
results suggest that AT1 receptor blockade may not be
beneficial in patients who have recent onset of moderate to
severe MR due to mitral valve prolapse.
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